CC BY-NC-ND 4.0 · South Asian J Cancer 2023; 12(01): 001-008
DOI: 10.1055/s-0043-1764227
Original Article
Cervical Cancer

Cervical Cancer in SAARC Countries

Purvish M. Parikh
1   Department of Clinical Hematology, Mahatma Gandhi University of Health Sciences and Technology, Jaipur, Rajasthan, India
2   Department of Medical Oncology, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India
3   Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
4   Department of Radiation Oncology, National Institute of ENT, Dhaka, Bangladesh
M M. Thinn
5   Department of Gynaecology, Yangon Central Women's Hospital, Yangon, Myanmar
6   Department of Medical Oncology, Patan Academy of Health Sciences, Kathmandu, Nepal
Ugyen Tshomo
7   Department of Gynaecology, Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan
Indu Mohan
8   Department of Community Medicine, Mahatma Gandhi University of Health Sciences and Technology, Jaipur, Rajasthan, India
9   Department of Gynaecological Oncology, Dharamshila Narayana Superspeciality Hospital, New Delhi, India
Nikhil Ghadyalpatil
10   Department of Medical Oncology, Yashoda Hospitals, Hyderabad, Telangana, India
› Author Affiliations


Zoom Image
Purvish M. Parikh

In the year 2020, a total of 342 000 women were estimated to die of cervical cancer, of which 90%) were expected amongst low- and middle-income countries (LMIC). Globally incidence of cervical cancer has reduced as a result of improved personal hygiene, better living conditions and higher application of opportunistic screening programs. Yet GLOBOCAN shows that absolute number of cases are still increasing.

We therefore conducted a 21 question multiple choice questionnaire online survey in Jan 2023 amongst 9 SAARC countries. A total of 367 replies were received and the representative answers for each country are being reported in this manuscript.

A good possibility of achieving World Health Assembly target (Nov 17, 2020) was felt only by Bhutan and Nepal. For screening, most countries (Bhutan, India, Myanmar, Nepal, Pakistan and Sri Lanka) recommend for all asymptomatic eligible patients. Public health experts have suggested VIA / VILI as the best solution for LMICs. However, a dual screening strategy (HPV DNA plus) cytology was preferred by doctors in Afghanistan, Bhutan, India, Myanmar, Pakistan and Sri Lanka.

Screening, triage and then treatment was the preferred by Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka.

HPV vaccination was recommended in all girls between ages 10 to 26 years in Bangladesh, India, Myanmar, Nepal, Pakistan and Sri Lanka. All the 9 countries would use HPV vaccination to all eligible patients if the cost of the vaccine was reasonably low.

Our survey clearly outlines challenges faced in tackling cervical cancer in SAARC countries. We also provide consensus regarding several potential solutions that can be used in both public and private cervical cancer control programs.

Publication History

Article published online:
25 February 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Estimates of the global burden of cervical cancer associated with HIV - The Lancet Global Health [Internet] [cited January 18, 2023]. Accessed January 30, 2023 at:
  • 2 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
  • 3 Singh M, Jha RP, Shri N, Bhattacharyya K, Patel P, Dhamnetiya D. Secular trends in incidence and mortality of cervical cancer in India and its states, 1990-2019: data from the Global Burden of Disease 2019 Study. BMC Cancer 2022; 22 (01) 149
  • 4 Cervical Cancer: Formulation and Implementation of Govt of India Guidelines for Screening and Management | SpringerLink [Internet] [cited January 18, 2023]. Accessed January 30, 2023 at:
  • 5 Dsouza JP, Van Den Broucke S, Pattanshetty S, Dhoore W. Exploring the barriers to cervical cancer screening through the lens of implementers and beneficiaries of the national screening program: a multi-contextual study. Asian Pac J Cancer Prev 2020; 21 (08) 2209-2215
  • 6 Mullapally SK, Digumarti L, Digumarti R. Cervical cancer in low- and middle-income countries: a multidimensional approach to closing the gaps. JCO Oncol Pract 2022; 18 (06) 423-425
  • 7 70,000 Ayushman Bharat-Health and Wellness Centres operationalised: Govt | Business Standard News [Internet].[cited January 18, 2023]. Accessed January 30, 2023 at:
  • 8 National Health Authority | GOI [Internet] [cited January 18, 2023]. Accessed January 30, 2023 at:
  • 9 Shastri SS, Mittra I, Mishra GA. et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst 2014; 106 (03) dju009
  • 10 Sankaranarayanan R, Esmy PO, Rajkumar R. et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370 (9585): 398-406
  • 11 Nene BM, Jayant K, Malvi SG, Dale PS, Deshpande R. Experience in screening for cervical cancer in rural areas of Barsi Tehsil (Maharashtra). Indian J Cancer 1994; 31 (01) 34-40
  • 12 Banerjee D, Mittal S, Mandal R, Basu P. Screening technologies for cervical cancer: overview. Cytojournal 2022; 19: 23
  • 13 Akazawa M, Hashimoto K. Artificial intelligence in gynecologic cancers: current status and future challenges - a systematic review. Artif Intell Med 2021; 120: 102164
  • 14 Bhatla N, Meena J, Kumari S, Banerjee D, Singh P, Natarajan J. Cervical cancer prevention efforts in India. Indian J Gynecol Oncol 2021; 19 (03) 41
  • 15 Lei J, Ploner A, Elfström KM. et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383 (14) 1340-1348
  • 16 Cervical cancer [Internet] [cited January 18, 2023]. Accessed January 30, 2023 at:
  • 17 Bhatla N, Dar L, Patro AR. et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?. Cancer Epidemiol 2009; 33 (06) 446-450
  • 18 Petignat P, Faltin DL, Bruchim I, Tramèr MR, Franco EL, Coutlée F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007; 105 (02) 530-535
  • 19 Ahmed D, VanderEnde K, Harvey P. et al. Human papillomavirus (HPV) vaccine introduction in Sikkim state: best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019. Vaccine 2022; 40 (Suppl 1): A17-A25
  • 20 Serum Institute of India - News [Internet] [cited January 18, 2023]. Accessed January 30, 2023 at: